Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
10.55
+0.13 (1.25%)
At close: Oct 24, 2025, 4:00 PM EDT
10.40
-0.15 (-1.42%)
After-hours: Oct 24, 2025, 4:48 PM EDT
Amneal Pharmaceuticals Employees
Amneal Pharmaceuticals had 8,300 employees as of December 31, 2024. The number of employees increased by 450 or 5.73% compared to the previous year.
Employees
8,300
Change (1Y)
450
Growth (1Y)
5.73%
Revenue / Employee
$343,725
Profits / Employee
$407
Market Cap
3.31B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8,300 | 450 | 5.73% |
| Dec 31, 2023 | 7,850 | 250 | 3.29% |
| Dec 31, 2022 | 7,600 | 600 | 8.57% |
| Dec 31, 2021 | 7,000 | 1,000 | 16.67% |
| Dec 31, 2020 | 6,000 | 500 | 9.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AMRX News
- 25 days ago - Amneal to Report Third Quarter 2025 Results on October 30, 2025 - GlobeNewsWire
- 4 weeks ago - Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab) - GlobeNewsWire
- 4 weeks ago - Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% - GlobeNewsWire
- 6 weeks ago - Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution - GlobeNewsWire
- 6 weeks ago - Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps Growing - Seeking Alpha
- 7 weeks ago - Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension - GlobeNewsWire
- 2 months ago - Amneal Pharmaceuticals, Inc. (AMRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico - GlobeNewsWire